Skip to Content
Merck
All Photos(1)

Documents

171610

Sigma-Aldrich

Anti-Amyloid Precursor Protein, C-Terminal (751-770) Rabbit pAb

liquid, Calbiochem®

Synonym(s):

Anti-0443, Anti-APP-CT20

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

UNSPSC Code:
12352203
NACRES:
NA.43

biological source

rabbit

Quality Level

100

antibody form

serum

antibody product type

primary antibodies

clone

polyclonal

form

liquid

species reactivity

human

manufacturer/tradename

Calbiochem®

storage condition

OK to freeze

isotype

IgG

shipped in

ambient

storage temp.

−20°C

target post-translational modification

unmodified

General description

Anti-Amyloid Precursor Protein, C-Terminal (751-770), rabbit polyclonal, recognizes full-length APP and C-terminal soluble products CTFα, β, and γ. It is validated for WB, IF, IHC, and IP.
Rabbit polyclonal antibody supplied as undiluted serum. Recognizes full-length APP and C-terminal soluble products CTFγ (~6 kDa), CTFα (~9 kDa), and CTFβ (~11 kDa).
Recognizes full-length APP and C-terminal soluble products CTFγ (~6 kDa), CTFα (~9 kDa), and CTFβ (~11 kDa).
  • Antibody Target Gene Symbol: APP
  • Target Synonym: AAA, AD1, Adap, AL024401, Amyloid precursor, Amyloidogenic glycoprotein, APP isoform 1, APPI, appican, CTFgamma, CVAP, E030013M08RIK, Nexin II, P3, PN2, PreA4, PROTEASE NEXIN2
  • Entrez Gene Name: amyloid beta (A4) precursor protein
  • Hu Entrez ID: 351 (Related Antibodies: PC729, PC152,PC151, PC150, PC149, NE1012,171609, 171608, 171607, 171606, 171605, 171604, 171603, 171598, 171537)
  • Mu Entrez ID: 11820
  • Rat Entrez ID: 54226

    • Immunogen

    Human
    a synthetic peptide [(C)KMQQNGYENPTYKFFEQMQN] corresponding to amino acids 751-770 of human precursor protein (APP), conjugated to KLH

    Application

    Immunoblotting (1:5000-1:20,000)

    Immunofluorescence (1:1000)

    Immunohistochemistry (1:1000)

    Immunoprecipitation (1:1000)

    Warning

    Toxicity: Standard Handling (A)

    Reconstitution

    Following initial thaw, aliquot and freeze (-20°C).

    Other Notes

    Pinnix, I., et al. 2001. J. Biol. Chem.276, 481.
    Variables associated with assay conditions will dictate the proper working dilution.

    Legal Information

    Purchase of this material is for research use only. Users are invited to request a license from Mayo prior to using the 0433 antibody or any derivatives for clinical diagnostic or therapeutic purposes. For license information, please contact: Mayo Medical Ventures, Office of Technology Commercialization (507) 284-8878, 200 First Street SW, Rochester, MN 55905-001.
    CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

    Not finding the right product?  

    Try our Product Selector Tool.

    Storage Class Code

    10 - Combustible liquids

    WGK

    WGK 1

    Flash Point(F)

    Not applicable

    Flash Point(C)

    Not applicable

    Certificates of Analysis (COA)

    Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

    Already Own This Product?

    Find documentation for the products that you have recently purchased in the Document Library.

    Visit the Document Library

    Dario Tejera et al.
    The EMBO journal, 38(17), e101064-e101064 (2019-07-31)
    Alzheimer's disease is the most prevalent type of dementia and is caused by the deposition of extracellular amyloid-beta and abnormal tau phosphorylation. Neuroinflammation has emerged as an additional pathological component. Microglia, representing the brain's major innate immune cells, play an
    Inderjeet Saluja et al.
    Neurobiology of disease, 36(1), 162-168 (2009-07-28)
    The neuronal adaptor protein X11alpha/mint-1/APBA-1 binds to the cytoplasmic domain of the amyloid precursor protein (APP) to modulate its trafficking and metabolism. We investigated the consequences of reducing X11alpha in a mouse model of Alzheimer's disease (AD). We crossed hAPPswe/PS-1DeltaE9
    Ramon Velazquez et al.
    Aging cell, 18(6), e13037-e13037 (2019-09-29)
    Currently, there are no effective therapies to ameliorate the pathological progression of Alzheimer's disease (AD). Evidence suggests that environmental factors may contribute to AD. Notably, dietary nutrients are suggested to play a key role in mediating mechanisms associated with brain
    Ramon Velazquez et al.
    Molecular psychiatry, 25(10), 2620-2629 (2019-01-10)
    The lack of effective treatments for Alzheimer's disease (AD) is alarming, considering the number of people currently affected by this disorder and the projected increase over the next few decades. Elevated homocysteine (Hcy) levels double the risk of developing AD.
    Giselle P Lim et al.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 25(12), 3032-3040 (2005-03-25)
    Epidemiological studies suggest that increased intake of the omega-3 (n-3) polyunsaturated fatty acid (PUFA) docosahexaenoic acid (DHA) is associated with reduced risk of Alzheimer's disease (AD). DHA levels are lower in serum and brains of AD patients, which could result
    View All Related Papers

    Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

    Contact Technical Service